ACTG presentations are listed below by day and time:
MONDAY, MARCH 4th
A FIRST-IN-HUMAN STUDY OF THE TRISPECIFIC HIV-1 BROADLY NEUTRALIZING ANTIBODY, SAR441236 (ACTG 5377; Oral Presentation: Monday, March 4, 10:29 am MT, Mile High Ballroom 1-2-3) Athe Tsibris, et al.
SAFETY AND EFFICACY OF VRC07-523LS PLUS LONG-ACTING CABOTEGRAVIR IN THE PHASE 2 ACTG A5357 TRIAL (ACTG 5357; Oral Presentation: Monday, March 4, 11:00 am MT, Mile High Ballroom 1-2-3) Babafemi O. Taiwo, et al.
INTACT HIV RESERVOIR LEVELS ARE STABLE AFTER SHORT-TERM ART INTERRUPTION (ACTG 5345; Themed Discussion, Monday, March 4, 1:45 pm MT, Four Seasons Ballroom 2-3) Prerana Shrestha, et al.
COMMON T CELL FEATURES PREDICTING TIME TO REBOUND IN INTERVENTIONAL AND NON-INTERVENTIONAL TREATMENT (NWCS 463; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Tongcui Ma, et al.
BASELINE KSHV T CELL RESPONSES ARE ASSOCIATED WITH PRE-TREATMENT CLINICAL PRESENTATION IN KS (ACTG 5263/5264; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Ralph Kamel, et al.
Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE (ACTG 5332; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Steve Grinspoon, et al.
ASSOCIATIONS BETWEEN NADIR CD4 AND SUBSEQUENT IMMUNE MEASURES WITH LONG-TERM COGNITIVE FUNCTION IN HAILO (ACTG 5322; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Frank Joseph Palella, et al.
Pro-Inflammatory Glycomic Dysregulations Define HIV-Associated Neurocognitive Impairments (NWCS 539; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Leila B. Giron, et al.
ASSESSING BLOOD-BASED BIOMARKERS AS PREDICTORS OF COGNITIVE DECLINE IN PWH: ACTG A5322 (HAILO) (NWCS 544; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Shibani S. Mukerji, et al.
PHENOTYPING RISK OF POLYPHARMACY AND COGNITIVE IMPAIRMENT IN ACTG A5322 (“HAILO”) (NWCS 491; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Robert Paul, et al.
POPULATION PHARMACOKINETIC APPROACHES TO STANDARDIZE ANTIVIRAL EXPOSURE IN THE CEREBROSPINAL FLUID (ACTG 5321; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Sean Avedissian, et al.
AAV-1, -8, and -9 seroprevalence in Healthy Donors and People Living with HIV in Sub-Saharan Africa (ACTG 5175; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Giselle Lopez Fernandez, et al.
A NEW MEASURE OF ART ACTIVITY IN CSF AND ASSOCIATION WITH PERSISTENCE AND COGNITIVE FUNCTION (ACTG 5321; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Sean N. Avedissian, et al.
PHARMACOGENETICS OF DOLUTEGRAVIR DURING RIFAPENTINE/ISONIAZID TREATMENT OF LATENT TB IN ACTG A5372 (ACTG 5372; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Nia Covington, et al.
MONOCYTE ACTIVATION IN PERSONS WITH HIV AND LATENT TUBERCULOSIS CO-INFECTION IN THE ACTG A5279/BRIEF TB TRIAL (NWCS 476; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Moises A. Huaman, et al.
RE-INFECTION FOLLOWING A MINIMAL MONITORING APPROACH FOR TREATMENT OF HEPATITIS C VIRUS INFECTION (ACTG 5360; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Win Min Han, et al.
EFFECTS OF SEMAGLUTIDE ON MUSCLE STRUCTURE AND FUNCTION IN THE SLIM LIVER STUDY (ACTG 5371; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Grace L. Ditzenberger, et al.
A PHASE II TRIAL OF 4 WEEKS OF GLECAPREVIR/PIBRENTASVIR FOR EARLY HEPATITIS C VIRUS (ACTG 5380; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Arthur Y. Kim, et al.
PREDICTORS OF LONG COVID IN UNTREATED ADULTS WITH MILD-TO-MODERATE COVID-19 (ACTG 5401; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Teresa H. Evering, et al.
ASSOCIATION OF LONG COVID WITH HEALTH-RELATED QUALITY-OF-LIFE OUTCOMES (ACTG 5401; Poster Presentation: Monday, March 4, 2:30 pm MT, Poster Hall C-D) Malini M. Gandhi, et al.
TUESDAY MARCH 5th
PITAVASTATIN REDUCES NON-CALCIFIED PLAQUE VIA PRO-COLLAGEN PCOLCE INDEPENDENTLY OF LDL IN REPRIEVE (ACTG 5333s; Oral Presentation: Tuesday, March 5, 10:29 am MT, Mile High Ballroom 1-2-3) Márton Kolossváry, et al.
SEMAGLUTIDE REDUCES METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE IN PEOPLE WITH HIV: THE SLIM LIVER STUDY (ACTG 5371; Oral Presentation: Tuesday, March 5, 10:29 am MT, Four Seasons Ballroom) Jordan Lake, et al.
PITAVASTATIN HAS NO EFFECT ON LONG-TERM, OBJECTIVE PHYSICAL FUNCTION IN REPRIEVE (ACTG 5361s; Oral Presentation: Tuesday, March 5, 11:00 am MT, Mile High Ballroom 1-2-3) Kristine Erlandson, et al.
PROVISIONAL RESULTS FROM A 3-MONTH CLOFAZIMINE/RIFAPENTINE-CONTAINING REGIMEN FOR DS-TB (ACTG 5362; Oral Presentation: Tuesday, March 5, 11:32 am MT, Four Seasons Ballroom) John Metcalfe, et al.
PERFORMANCE OF THE ACC/AHA POOLED COHORT EQUATIONS FOR RISK PREDICTION IN THE GLOBAL REPRIEVE TRIAL (ACTG 5332; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D), Steven Grinspoon, et al.
FACTORS AFFECTING RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG PEOPLE WITH HIV IN REPRIEVE (ACTG 5332; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D) Steven Grinspoon, et al.
PROTEIN MODIFICATIONS BY LACTATE ASSOCIATE WITH A LOWER RISKS OF NEUROCOGNITIVE IMPAIRMENT (NCI) AND DEATH (NWCS 447; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D) Robert Kalayjian, et al.
Reduced HIV RNA Transcription During Long-Term ART is Associated with Increased Ki67+ CD8+ T Cells (NWCS 443; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D) Alan Wells, et al.
VARIABLE PERSISTENCE OF NON-SUPPRESSIBLE VIREMIA ON ANTIRETROVIRAL THERAPY (ACTG 5321; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D) Elias K. Halvas, et al.
EFFECTS OF PITAVASTATIN ON COVID-19 INCIDENCE AND SERIOUSNESS AMONG PEOPLE WITH HIV (ACTG 5332; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D) Steven Grinspoon, et al.
VIRAL AND SYMPTOM REBOUND AFTER COVID-19 MONOCLONAL ANTIBODY THERAPY IN THE ACTIV-2 TRIAL (ACTG 5401; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D) Kara Chew, et al.
PHARMACOKINETICS OF TECOVIRIMAT IN PERSONS WITH MPOX: RESULTS FROM ACTG 5418 (ACTG 5418; Poster Presentation: Tuesday, March 5, 2:30 pm MT, Poster Hall C-D) Zixuan Wei, et al.
WEDNESDAY, MARCH 6th
HEPB-CPG VACCINE IS SUPERIOR TO HEPB-ALUM IN PEOPLE WITH HIV AND PRIOR VACCINE NON-RESPONSE (ACTG 5379; Oral Presentation: Wednesday, March 6, 12:28 pm MT, Mile High Ballroom 1-2-3) Kristen Marks, et al.
LONG-ACTING INJECTABLE CAB/RPV IS SUPERIOR TO ORAL ART IN PWH WITH ADHERENCE CHALLENGES (ACTG 5359; Oral Presentation: Wednesday, March 6, 12:52 pm MT, Mile High Ballroom 1-2-3) Aadia Rana, et al.
SUPPRESSING ASYMPTOMATIC CMV WITH LETERMOVIR RESHAPES PLASMA PROTEOME IN TREATED PEOPLE WITH HIV (PWH) (ACTG 5383; Poster Presentation: Wednesday, March 6, 2:30 pm MT, Poster Hall C-D) Sara Gianella Weibel, et al.
T CELL SUBSETS AND INCIDENCE OF DIABETES IN PERSONS WITH HIV (DACS 357/1; Poster Presentation: Wednesday, March 6, 2:30 pm MT, Poster Hall C-D) Frank Palella, et al.
HIV POST-TREATMENT CONTROLLERS SHOW ENHANCED CD8+ T CELL PROLIFERATIVE CAPACITY AFTER ART CESSATION (NWCS 470; Poster Presentation: Wednesday, March 6, 2:30 pm MT, Poster Hall C-D) Charles R. Crain, et al.
EARLIER INITIATION OF ART REDUCES INTACT PROVIRUSES BUT NOT RESIDUAL VIREMIA AFTER 48 WEEKS (ACTG 5354; Poster Presentation: Wednesday, March 6, 2:30 pm MT, Poster Hall C-D) Joshua Cyktor, et al.
VIROLOGIC AND RESISTANCE OUTCOMES AFTER SWITCH TO TLD FOR FAILING 1ST OR 2ND LINE ART (ACTG 5381; Poster Presentation: Wednesday, March 6, 2:30 pm MT, Poster Hall C-D) Caitlyn McCarthy, et al.
CIRCULATING IMMUNOREGULATORY PROTEINS INDICATIVE OF POOR CD4 RECOVERY IN PEOPLE WITH HIV ON ART (NWCS 563; Poster Presentation: Wednesday, March 6, 2:30 pm MT, Poster Hall C-D) Preeti Moar, et al.
A SKEWED NK CELL REPERTOIRE PERSISTS IN PEOPLE WITH HIV-1 DESPITE LONG-TERM ART (NWCS 486; Poster Presentation: Wednesday, March 6, 2:30 pm MT, Poster Hall C-D) Renee R. Anderko, et al.